nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A CASE OF B-CELL LYMPHOBLASTIC LYMPHOMA WITH PRIMARY BONE INVOLVEMENT: A MIMICKER OF RHEUMATOLOGICAL AND INFECTIOUS DISEASE
|
Morales, S. |
|
|
121 |
S |
p. S73 |
artikel |
2 |
ADOLESCENT AGE AT DIAGNOSIS MAY NEGATIVELY IMPACT CLINICAL OUTCOMES IN PEDIATRIC POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
|
Reddy, S. |
|
|
121 |
S |
p. S57-S58 |
artikel |
3 |
ALK+ ALCL EVADES IMMUNE SURVEILLANCE THROUGH NPM-ALK-DRIVEN EPIGENETIC REPRESSION OF Cd48
|
Wu, R. |
|
|
121 |
S |
p. S3 |
artikel |
4 |
ALK INHIBITOR PLUS VINBLASTINE FOR REFRACTORY/RELAPSED PEDIATRIC ALK+ ANAPLASTIC LARGE CELL LYMPHOMA: A PROSPECTIVE, ONE-ARM, OPEN-LABEL REAL-WORLD STUDY
|
Wang, S. |
|
|
121 |
S |
p. S66-S67 |
artikel |
5 |
ALK INHIBITORS SAFETY PROFILE IN PEDIATRIC PATIENTS TREATED FOR AN ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA: REAL LIFE EXPERIENCE AMONG A FRENCH COHORT
|
d’Hautefeuille, C. |
|
|
121 |
S |
p. S68-S69 |
artikel |
6 |
ALK INIHIBITOR THERAPY IN ALCL
|
Sekimizu, M. |
|
|
121 |
S |
p. S63 |
artikel |
7 |
A MULTICENTER PILOT STUDY USING INDUCTION CHEMO-IMMUNOTHERAPY FOLLOWED BY CONSOLIDATION WITH REDUCED TOXICITY CONDITIONING AND ALLOGENEIC STEM CELL TRANSPLANT IN ADVANCED STAGE MATURE NON-APLASTIC T/NK-CELL LYMPHOMA/ LEUKEMIA IN CHILDREN, ADOLESCENT, AND YOUNG ADULTS (CAYA)
|
Xavier, A. |
|
|
121 |
S |
p. S26 |
artikel |
8 |
ANAPLASTIC LYMPHOMA KINASE INHIBITION ACTIVATES AUTOPHAGY IN ALK+ ANAPLASTIC LARGE CELL LYMPHOMA
|
Hoogstra, D. |
|
|
121 |
S |
p. S67-S68 |
artikel |
9 |
A NOVEL CYTOKINE-ANTIBODY FUSION PROTEIN, N-820, TO ENHANCE THE FUNCTIONS OF EX-VIVO EXPANDED NATURAL KILLER CELLS AGAINST BURKITT LYMPHOMA
|
Chu, Y. |
|
|
121 |
S |
p. S17-S18 |
artikel |
10 |
A NOVEL PATHOGENIC SH2D1A MUTATION CAUSES X-LINKED LYMPHOPROLIFERATIVE DISEASE MANIFESTED BY NON-HODGKIN LYMPHOMA AND DYSGAMMAGLOBULINEMIA
|
Gilad, G. |
|
|
121 |
S |
p. S44-S45 |
artikel |
11 |
AN UNUSUAL PRESENTATION OF A RARE PEDIATRIC DISEASE
|
Patel, G. |
|
|
121 |
S |
p. S52 |
artikel |
12 |
A PEDIATRIC BURKITT LYMPHOMA PATIENT-DERIVED XENOGRAFT RESOURCE OF PRIMARY AND RELAPSE/REFRACTORY DISEASE
|
Steel, C. |
|
|
121 |
S |
p. S48-S49 |
artikel |
13 |
A PHASE I TRIAL OF TARGETED IMMUNOTHERAPY WITH DARATUMUMAB FOLLOWING MYELOABLATIVE TOTAL BODY IRRADIATION (TBI)-BASED CONDITIONING AND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATON IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH HIGH-RISK T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOMA (T- ALL/T-LLy) (ALLO-T-DART) (IND 159396): A PTCTC FACILITATED STUDY
|
Quigg, T. |
|
|
121 |
S |
p. S71-S73 |
artikel |
14 |
A RARE CASE OF PRIMARY CUTANEOUS PRECURSOR T-CELL LYMPHOBLASTIC LYMPHOMA IN A BRAZILIAN CHILD
|
Barlera, T. |
|
|
121 |
S |
p. S71 |
artikel |
15 |
A RARE CASE OF PRIMARY OCULAR POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN A BRAZILIAN CHILD
|
Barlera, T. |
|
|
121 |
S |
p. S54 |
artikel |
16 |
A TARGETED GENE EXPRESSION CLASSIFIER IDENTIFIES PEDIATRIC T-ALL PATIENTS AT HIGH RISK FOR END INDUCTION MINIMAL RESIDUAL DISEASE POSITIVITY
|
Meyer, L. |
|
|
121 |
S |
p. S34-S35 |
artikel |
17 |
A UK POPULATION-BASED STUDY OF NON-HODGKIN LYMPHOMA IN ADOLESCENTS AND YOUNG ADULTS: TREATMENT-RELATED OUTCOMES FOR DIFFUSE LAREG B-CELL
|
Carr, R. |
|
|
121 |
S |
p. S59 |
artikel |
18 |
B-CELL NHL RELAPSES IN PPLLSG PATIENTS IN YEARS 2004–2021
|
Latos-Grażyńska, E. |
|
|
121 |
S |
p. S20-S21 |
artikel |
19 |
BCR EXPRESSION IN BURKITT LYMPHOMA: NEW INSIGHT IN MUTATIONAL LANDSCAPE
|
Siciliano, M. |
|
|
121 |
S |
p. S1-S2 |
artikel |
20 |
BLOCKING THE BCL10-MALT1 INTERACTION IN DIFFUSE LARGE B-CELL LYMPHOMA
|
Maurer, L. |
|
|
121 |
S |
p. S23 |
artikel |
21 |
BONE MARROW INFILTRATION AS A PROGNOSTICE FACTOR IN PEDIATARIC BURKITT LYMPHOMA PATIENTS
|
Rahman, H. |
|
|
121 |
S |
p. S38 |
artikel |
22 |
BRENTUXIMAB-BENDAMUSTINE IN CHILDREN, ADOLESCENT AND YOUNG ADULTS WITH RELAPSED/REFRACTORY ANAPLASTIC LARGE CELL LYMPHOMA
|
Vinti, L. |
|
|
121 |
S |
p. S65 |
artikel |
23 |
BRENTUXIMAB VEDOTIN PLUS VIGEPP CHEMOTHERAPY FOR RELAPSED/REFRACTORY ADOLESCENT HODGKIN LYMPHOMA
|
Tsaplina, N. |
|
|
121 |
S |
p. S60 |
artikel |
24 |
BRIGATINIB SHOWS PRECLINICAL PROMISE FOR AGGRESSIVE RELAPSED/REFRACTORY AK = LK-POSITIVE ALCL
|
Matthews, J. |
|
|
121 |
S |
p. S16-S17 |
artikel |
25 |
“BURKITT-LIKE LYMPHOMA WITH 11Q ABERRATION”: NEITHER BURKITT-LYMPHOMA NOR DIFFUSE LARGE B-CELL LYMPHOMA. WHAT THE MICROENVIRONMENT TELLS US
|
Del Corvo, M. |
|
|
121 |
S |
p. S46 |
artikel |
26 |
BURKITT LYMPHOMA AND HIGH-GRADE B-CELL LYMPHPHOMA WITH 11q ABBERRATIONS SHARE A TRANSCRIPTIONAL PROFILE RESEMBLING A SUBPOPULATION OF EARLY DARK ZONE CELLS
|
Di Stefano, G. |
|
|
121 |
S |
p. S3-S4 |
artikel |
27 |
CD72 NANOBODY CAR-T CELLS HAVE POTENT ANTITUMOR EFFICACY IN B CELL MALIGNANCIES
|
Temple, W. |
|
|
121 |
S |
p. S8 |
artikel |
28 |
CENTRAL NERVOUS SYSTEM INVOLVEMENT IN PEDIATRIC ANAPLASTIC LARGE T-CELL LYMPHOMA
|
Rocco, A. |
|
|
121 |
S |
p. S54-S55 |
artikel |
29 |
CHARACTERISTICS AND OUTCOME OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AFTER SOLID ORGAN TRANSPLANTATION
|
Vergote, V. |
|
|
121 |
S |
p. S26 |
artikel |
30 |
CHARACTERIZATION OF IG-MYC-BREAKPOINTS AND THEIR APPLICATION FOR QUANTITATIVE MINIMAL DISEASE MONITORING IN HIGH-RISK PEDIATRIC BURKITT-LYMPHOMA AND –LEUKEMIA
|
Damm-Welk, C. |
|
|
121 |
S |
p. S22 |
artikel |
31 |
CHARACTERIZING THROMBOSIS IN CHILDREN & ADOLESCENTS WITH PRIMARY MEDIASTINAL B-CELL LYMPHOMA
|
Karsenty, C. |
|
|
121 |
S |
p. S58 |
artikel |
32 |
CHILDHOOD AND ADOLESCENT HODGKIN REED-STERNBERG CELLS DEMONSTRATE UNIQUE GENE EXPRESSION SIGNATURE CONSISTENT WITH ONCOGENIC-INDUCED SENESCENCE
|
Agrusa, J. |
|
|
121 |
S |
p. S10 |
artikel |
33 |
CLINICAL FEATURES AND TREATMENT OUTCOME OF CHILDREN WITH LYMPHOBLASTIC LYMPHOMA IN TAIWAN
|
Chen, S. |
|
|
121 |
S |
p. S70 |
artikel |
34 |
CLINICAL SPECTRUM OF PRECURSOR B-CELL LYMPHOBLASTIC MALIGNANCIES: A LARGE COHORT STUDY OF 364 PEDIATRIC PATIENTS
|
Kroeze, E. |
|
|
121 |
S |
p. S21 |
artikel |
35 |
CLINICOPATHOLOGIC FEATURES AND PROGNOSIS OF PEDIATRIC HIGH-GRADE B-CELL LYMPHOMA: A MULTICENTER ANALYSIS
|
Zhao, Y. |
|
|
121 |
S |
p. S42-S43 |
artikel |
36 |
COMBINATION TREATMENT WITH VINBLASTINE AND CRIZOTINIB IN PEDIATRIC ANAPLASTIC LARGE CELL LYMPHOMA
|
Knörr, F. |
|
|
121 |
S |
p. S66 |
artikel |
37 |
COMBINED BORTEZOMIB AND VENETOCLAX TARGETS THE PRO-SURVIVAL FUNCTIONS OF LATENT VIRAL PROTEINS IN EPSTEIN-BARR VIRUS-DRIVEN LYMPHOPROLIFERATIVE DISEASES
|
Chiang, A. |
|
|
121 |
S |
p. S25 |
artikel |
38 |
COMBINED BRENTUXIMAB VEDOTIN AND NIVOLUMAB FOR TREATMENT OF RELAPSED/REFRACTORY PEDIATRIC HOGDKIN LYMPHOMA AND GREY ZONE LYMPHOMA
|
Lam, G. |
|
|
121 |
S |
p. S56-S57 |
artikel |
39 |
Contents
|
|
|
|
121 |
S |
p. iii |
artikel |
40 |
DEFINING THE SYSTEMIC IMMUNE LANDSCAPE IN CHILDREN AT AN INCREASED RISK OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE: THE IMMUNOLOGY OF THYMECTOMY AND CHILDHOOD CARIDAC TRANSPLANT (ITHACA) STUDY
|
Offor, U. |
|
|
121 |
S |
p. S56 |
artikel |
41 |
DIAGNOSTIC AND THERAPEUTIC CHALLENGES IN PATIENTS WITH ALAPLASTIC NHL AND LONG QT SYNDROME
|
Maciejka-Kemblowska, L. |
|
|
121 |
S |
p. S65-S66 |
artikel |
42 |
EBV-DRIVEN LYMPHOID NEOPLASMS ASSOCIATED WITH ALL MAINTENANCE THERAPY: AN INTERNATIONAL OBSERVATINAL STUDY
|
Elitzur, S. |
|
|
121 |
S |
p. S5 |
artikel |
43 |
Editorial Board
|
|
|
|
121 |
S |
p. ii |
artikel |
44 |
EFFICACY AND SAFETY OF SEQUENTIAL DIFFERENT B CELL ANTIGEN-TARGETED CAR T-CELL THERAPY FOR PEDIATRIC REFRACTORY/ RELAPSED BURKITT LYMPHOMA WITH SECONDARY CENTRAL NERVOUS SYSTEM INVOLVEMENT
|
Liu, Y. |
|
|
121 |
S |
p. S32-S33 |
artikel |
45 |
EPSTEIN-BARR VIRUS ORCHESTRATE THE TUMOR MICROENVIRONMENT OF BURKITT LYMPHOMA
|
Siciliano, M. |
|
|
121 |
S |
p. S9 |
artikel |
46 |
ESTABLISHING THE OPTIMAL WAY TO ADMINISTER ANAPLASTIC LYMPHOMA KINASE (ALK) TYROSINE KINASE INHIBITORS (TKIs) IN PAEDIATRIC ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) TO PREVENT/ DELAY RESISTANCE GENERATION
|
Hare, L. |
|
|
121 |
S |
p. S36-S37 |
artikel |
47 |
EXCELLENT OUTCOME OF CHILDREN/ADOLESCENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA TREATED WITH LMB-BASED CHEMOTHERAPY WITH RITUXIMAB
|
Dourthe, M. |
|
|
121 |
S |
p. S10-S11 |
artikel |
48 |
FDG-PET/CT IMAGING IN PEDIATRIC PRECURSOR B-CELL LYMPHOBLASTIC LYMPHOMA (BCP-LBL) SHOWS BONE (MARROW) INVOLVEMENT IN A VAST MAJORITY OF PATIENTS
|
Kroeze, E. |
|
|
121 |
S |
p. S73-S74 |
artikel |
49 |
18F-FDG-PET/CT IN THE ASSESSMENT OF BONE MARROW INVOLVEMENT IN PEDIATRIC NON-HODGKIN LYMPHOMA- A SINGLE CENTER EXPEREIENCE
|
Siri, M. |
|
|
121 |
S |
p. S19-S20 |
artikel |
50 |
FLOW CYTOMETRY OF CEREBROSPINAL FLUID FOR DETECTION OF CENTRAL NERVOUS SYSTEM INVOLVEMENT IN CHILDHOOD NON-HODGKIN LYMPHPOMA
|
Thastrup, M. |
|
|
121 |
S |
p. S49 |
artikel |
51 |
FULMINANT, EBV DRIVEN PLASMACYTIC POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) WITH LOSS OF 1P AND GAIN OF TP53/CEP17 AND IGH BONE MARROW INVOLVEMENT AFTER LIVER TRANSPLANT IN 17-MONTH OLD BOY
|
Pavasovic, V. |
|
|
121 |
S |
p. S53-S54 |
artikel |
52 |
FUNCTIONAL CHARACTERIZATION OF POTENTIAL DIAGNOSTIC TARGETS IN BURKITT-NHL
|
te Vrugt, M. |
|
|
121 |
S |
p. S47-S48 |
artikel |
53 |
GEMCITABINE, OXALIPLATIN, AND ANTI-CD20 THERAPY IS SAFE AND EFFECTIVE IN CHILDREN AND YOUNG ADULTS WITH NON-HODGKIN LYMPHOMA UNFIT FOR INTENSIVE THERAPY
|
Bender, J. |
|
|
121 |
S |
p. S63-S64 |
artikel |
54 |
GENOME-WIDE GENOMIC ABNORMALITIES AND FUNCTIONAL ESSENTIAL GENES IN BURKITT LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS
|
Zhou, P. |
|
|
121 |
S |
p. S21-S22 |
artikel |
55 |
GRK2, AN INHIBITOR OF MALT1-DEPEDENT ONCOGENIC SIGNALING, IS DOWNREGULATED BY microRNA IN ABC-DLBCL
|
Cheng, J. |
|
|
121 |
S |
p. S50 |
artikel |
56 |
IDENTIFICATION OF GENETIC PREDISPOSITION TO CHILDHOOD LYMPHOMAS – PRELIMINARY DATA
|
Szmyd, B. |
|
|
121 |
S |
p. S4 |
artikel |
57 |
IL10RA IS A CANDIDATE DRIVER GENE IN BURKITT-LIKE LYMPHOMA WITH 11q ABERRATION
|
Blain, A. |
|
|
121 |
S |
p. S50-S51 |
artikel |
58 |
IMMUNOGLOBULIN SUBCLASSES OF ANTI-ALK ANTIBODIES IN PEDIATRIC ANAPLASTIC LARGE CELL LYMPHOMA
|
Knörr, F. |
|
|
121 |
S |
p. S28 |
artikel |
59 |
IMPACT OF RITUXIMAB ON IMMUNE STATUS FOLLOWING THERAPY IN CHILDREN AND ADOLESCENTS WITH HIGH-RISK MATURE B-CELL NON-HODGKIN LYMPHOMA: RESULTS OF THE INTER-B-NHL RITUX 2010 TRIAL
|
Alexander, S. |
|
|
121 |
S |
p. S8-S9 |
artikel |
60 |
IMPROVING TREATMENT OUTCOMES FOR CHILDREN WITH ENDEMIC BURKITT LYMPHOMA (eBL) IN SUB-SAHARAN AFRICA (SSA)
|
Ferraresso, M. |
|
|
121 |
S |
p. S39-S40 |
artikel |
61 |
INHIBITION OF N6-METHYLADENOSINE (m6A) MODIFICATION AS A NOVEL TREATMENT STRATEGY FOR ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA (ALCL)
|
Mun, L. |
|
|
121 |
S |
p. S29 |
artikel |
62 |
INTER-B NHL-RITUX-2010 TRIAL FOR CHILDREN/ADOLESCENTS WITH HIGH-RISK MATURE B-NHL: SAFETY AND EFFICACY IN PATIENTS TREATED WITH RITUXIMAB AND LMB CHEMOTHERAPY
|
Minard-Colin, V. |
|
|
121 |
S |
p. S43 |
artikel |
63 |
INTERIM ANALYSIS OF CHINA-NET CHILDHOOD LYMPHOMA GROUP CNCL-NHL-2017 PROTOCOL IN THE TREATMENT OF CHILDREN WITH DIFFUSE LARGE B-CELL LYMPHOMA
|
Fu, Y. |
|
|
121 |
S |
p. S41-S42 |
artikel |
64 |
INTERMITTENT LORLATINIB DOSING IN RELAPSED/REFREACTORY ALCL PROVIDES RAPID AND DURABLE RESPONSES. FREQUENT MRD MEASUREMENT SUGGEST DRUG-DRIVEN DEPENDENCY DEPRIVATION MECHANISM
|
Sterba, J. |
|
|
121 |
S |
p. S64-S65 |
artikel |
65 |
IRF4 GENE REARRANGEMANT IN PEDIATRIC AND ADOLESCENT PATIENTS DIAGNOSED WITH LARGE B-CELL LYMPHOMA
|
Gooch, M. |
|
|
121 |
S |
p. S43 |
artikel |
66 |
IS A MODIFIED BFM REGIMEN WITH 1 Gram/m2 METHOTREXATE AS EFFECTIVE AS 5 Gram/m2 IN PEDIATRIC ADVANCED-STAGE NONLYMPHOBLASTIC NON-HODGKIN LYMPHOMA?
|
Kebudi, R. |
|
|
121 |
S |
p. S41 |
artikel |
67 |
LONG TERM PULMONARY AND CARDIAC FUNCTION AFFECTION AMONG NON-HODGKIN LYMPHOMA
|
Ayad, A. |
|
|
121 |
S |
p. S13 |
artikel |
68 |
MATURE B CELL NON-HODGKIN LYMPHOMA TREATMENT AND RESULTS IN A RETROSPECTIVE COHORT OF CHILDREN AND ADOLESCENTS TREATED BETWEEN 2016 AND 2020 IN LATIN AMERICA
|
Chantada, G. |
|
|
121 |
S |
p. S19 |
artikel |
69 |
MCL-1 INHIBITORS INDUCES APOPTOSIS IN VITRO IN BURKITT LYMPHOMA CELL LINES AND INHIBITS IN VIVO BURKITT LYMPHOMA PROGRESSION
|
Daly, T. |
|
|
121 |
S |
p. S64 |
artikel |
70 |
MiR-146a-5p IS ENRICHED IN PLASMA SMALL EXTRACELLULAR VESICLES OF PEDIATRIC ALCL PATIENTS WITH POOR PROGNOSIS AND HAS A ROLE IN MACROPHAGE POLARIZATION
|
Garbin, A. |
|
|
121 |
S |
p. S47 |
artikel |
71 |
MODELLING THE CLONAL EVOLUTION OF BURKITT LYMPHOMA USING PATIENT-DERIVED XENOGRAFTS
|
Chang, S. |
|
|
121 |
S |
p. S51 |
artikel |
72 |
MOLECULAR GENETICS ANALYSIS OF B-CELL PRECURSOR LYMPHOMA IN PEDIATRIC AND ADOLESCENT PATIENTS REVEALS HIGH FREQUENCY OF KMT2A TRANSLOCATIONS
|
Iaccarino, I. |
|
|
121 |
S |
p. S37 |
artikel |
73 |
MULTICENTER PILOT TRIAL OF INTRATHECAL LIPOSOMAL CYTARABINE IN CAYA WITH MATURE DE-NOVO B-NHL
|
Goldman, S. |
|
|
121 |
S |
p. S34 |
artikel |
74 |
MULTI-INSTITUTIONAL EXPERIENCE OF FENTANYL FOR BROWN FAT MITIGATION IN 18FDG-PET/CT FOR PEDIATRIC ONCOLOGY PATIENTS
|
Gaylord, W. |
|
|
121 |
S |
p. S48 |
artikel |
75 |
NONCODING RNAs IN BURKITT LYMPHOMA
|
López, C. |
|
|
121 |
S |
p. S2 |
artikel |
76 |
NON-GERMINAL CENTER B-CELL SUBTYPE OF PEDIATRIC DISFFUSE LARGE B-CELL LYMPHOMA IN JAPAN: A MULTI-CASE ANALYSIS
|
Hori, D. |
|
|
121 |
S |
p. S1 |
artikel |
77 |
NON-HODGKIN LYMPHOMA PRESENTING WITH SPINAL CORD COMPRESSION: A POPULATION-BASED ANALYSIS ON THE NHL-BFM STUDY GROUP
|
Riquelme, A. |
|
|
121 |
S |
p. S62 |
artikel |
78 |
OBINUTUZUMAB (GA101) VS. RITUXIMAB SIGNIFICANTLY ENHANCES CELL DEATH, ANTIBODY-DEPENDENT CYTOTOXICITY AND IMPROVES OVERALL SURVIVAL AGAINST CD20+ PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBL) IN A XENOGRAFT NOD-SCID IL2RGNULL (NSG) MOUSE MODEL: A POTENTIAL TARGETED AGENT IN THE TREATMENT OF PMBL
|
Chu, Y. |
|
|
121 |
S |
p. S14 |
artikel |
79 |
OMITTING RADIATION IN YOUNG ADULT FEMALES WITH HODGKIN’S DISEASE, IS THERE AN IMPACT ON OUTCOME??
|
Semary, S. |
|
|
121 |
S |
p. S59-S60 |
artikel |
80 |
OPTIMIZING CHIMERIC ANTIGEN RECEPTOR (CAR) ENGINEERED NK CELL-MEDIATED CYTOTOXICITY COMBINED WITH ANTI-CD 20 OR ANTI-CD79 THERAPEUTIC ANTIBODIES AND NKTR-255 IN BURKITT LYMPHOMA (BL)
|
Chu, Y. |
|
|
121 |
S |
p. S27 |
artikel |
81 |
OUTCOME OF CHILDHOOD MATURE B-NHLs IN INDIA AND RELATION TO PROTOCOL USED-RESULTS OF A RETROSPECTIVE MULTI-CENTRE POOLED ANALYSIS
|
Moulik, N. |
|
|
121 |
S |
p. S38-S39 |
artikel |
82 |
OUTCOME OF CHILDREN TREATED FOR RECURRENT EPSTEIN-BARR VIRUS (EBV)-ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (PTLD)
|
Devine, K. |
|
|
121 |
S |
p. S26 |
artikel |
83 |
PDGFRβ DRIVES PROGRESSION BY ONCOGENE TRANSCRIPTION THROUGH STAT3/STAT5 HYPERACTIVATION IN ALCL
|
de los Fayos Alonso, I. Garces |
|
|
121 |
S |
p. S69 |
artikel |
84 |
PEDIATRIC AND YOUNG ADULT ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA GENETICALLY DIFFERS FROM THE ADULT COUNTERPART
|
Salmeron-Villalobos, J. |
|
|
121 |
S |
p. S29 |
artikel |
85 |
PEDIATRIC BIPHENOTYPIC NON-HODGKIN LYMPHOMA: A CASE REPORT AND REVIEW OF LITERATURE
|
Restivo, G. |
|
|
121 |
S |
p. S70-S71 |
artikel |
86 |
PEDIATRIC INFRADIAPHRAGMATIC HODGKIN’S LYMPHOMA: A UNIQUE IDENTITY
|
Eldeen, N. Ezz |
|
|
121 |
S |
p. S61 |
artikel |
87 |
PEDIATRIC LOW GRADE LYMPHOMAS: A REPORT FROM A SINGLE CENTRE
|
Kurucu, N. |
|
|
121 |
S |
p. S20 |
artikel |
88 |
PEDIATRIC NODAL MARGINAL ZONE LYMPHOMA AND PEDIATRIC-TYPE FOLLICULAR LYMPHOMA SHARE A COMMON MOLECULAR PROFILE
|
Salmeron-Villalobos, J. |
|
|
121 |
S |
p. S32 |
artikel |
89 |
PHASE 2 KEYNOTE-667 STUDY OF PEMBROLIZUMAB (PEMBRO) IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA (Chl) AND SLOW EARLY RESPONSE (SER) TO FRONTLINE CHEMOTHERAPY (CHEMO)
|
Vinti, L. |
|
|
121 |
S |
p. S33-S34 |
artikel |
90 |
PLASMA S-Evs miRNAs IN PEDIATRIC B-mALL: TUMOR BIOMARKERS AND TRANSFORMING FACTORS OF BONE MARROW NICHE
|
Damanti, C. |
|
|
121 |
S |
p. S47 |
artikel |
91 |
PLASMOBLASTIC LYMPHOMA (PBL) FOLLOWING LIVER TRANSPLANTATION. REPORT ON 2 PEDIATRIC PATIENTS
|
Dembowska-Baginska, B. |
|
|
121 |
S |
p. S52-S53 |
artikel |
92 |
POST-TRANSPLANT LYMPHOPROLIFERTIVE SYNDROME IN CHILDREN AND ADOLESCENTS UNDERGOING TRANSPLANTS HEPATIC AND RENAL: EPIDEMIOLOGICAL, DIAGNOSTIC AND THERAPY IN A BRAZILIAN
|
Luisi, F. |
|
|
121 |
S |
p. S26-S27 |
artikel |
93 |
PRELIMINARY RESULTS OF A PHASE 2 TRIAL OF OBINUTUZUMAB, IN COMBINATION WITH IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE (O-ICE) IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH RELAPSED/ REFRACTORY MATURE B-CELL NON-HODGKIN LYMPHOMA
|
Hochberg, J. |
|
|
121 |
S |
p. S62-S63 |
artikel |
94 |
PRE-TRANSPLANT TREATMENT OF HEPATISPLENIC T-CELL LYMPHOMA (GAMMA-DELATA): A PEDIATRIC CASE REPORT
|
Abel, M. |
|
|
121 |
S |
p. S53 |
artikel |
95 |
PROGNOSTIC SIGNIFICANCE OF PD1, PD-L1 EXPRESSION, PATHOLOGICAL SUBTYPES AND METABOLIC ACTIVITY ON 18F-FDG PET/CT IN REFRACTORY/RELAPSING PEDIATRIC HODGKIN LYMPHOMA
|
Khedr, R. |
|
|
121 |
S |
p. S61 |
artikel |
96 |
PROGNOSTIC VALUE OF INTERIM 18FDG-PET-CT IN MATURE B-CELL NON-HODGKIN LYMPHOMA
|
Aydin, B. |
|
|
121 |
S |
p. S42 |
artikel |
97 |
REDUCING CHEMORADIOTHERAPY AND RADIATION EXPOSURE FROM DIAGNOSTIC IMAGING BY UTILIZING TARGED IMMUNOTHERAPY IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS (CAYA) WITH MATURE LARGE B-CELL LYMPHOMA (RADICAL)
|
Audino, A. |
|
|
121 |
S |
p. S40 |
artikel |
98 |
REDUCING THE BURDEN OF ONCOLOGY CHEMORADIOTHERAPY AND RADIATION EXPOSURE FROM DIAGNOSTIC IMAGING BY UTILIZING TARGETED IMMUNOTHERAPY IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH LYMPHOMA (RADICAL, HODGKIN LYMPHOMA COHORT
|
Hochberg, J. |
|
|
121 |
S |
p. S11-S12 |
artikel |
99 |
REFINING THE GENETIC LANDSCAPE OF AGGRESSIVE B-CELL LYMPHOMA BY INTEGRATIVE MOLECULAR ANALYSIS
|
Mato, S. |
|
|
121 |
S |
p. S49 |
artikel |
100 |
REFRACTORY B-LYMPHOBLASTIC LYMPHOMA SUCCESSFULLY TREATED WITH TISAGENLECLEUCEL AND CONSOLIDATIVE STEM CELL TRANSPLANT
|
Dreyzin, A. |
|
|
121 |
S |
p. S70 |
artikel |
101 |
REPORT OF SYSTEMIC EBV-POSITIVE T-CELL LYMPHOMA OF CHILDHOOD ASSOCIATED WITH XMEN DISEASE CAUSED BY A NOVEL MUTATION
|
Man, J. |
|
|
121 |
S |
p. S55 |
artikel |
102 |
RESISTANCE TO ANAPLASTIC LYMPHOMA KINASE (ALK) TYROSINE KINASE INHIBITORS (TKIs) IN PAEDIATRIC ANAPLASTIC LARGE CELL LYMPHOMA (ALCL)
|
Hare, L. |
|
|
121 |
S |
p. S14-S16 |
artikel |
103 |
RITUXIMAB CLEARANCE IN PEDIATRIC PATIENTS WITH MAATURE B-CELL NON-HODGKIN LYMPHOMA
|
Tölle, I. |
|
|
121 |
S |
p. S23-S24 |
artikel |
104 |
SAFETY AND TOLERABILITY OF MYELOABLATIVE CONDITIONING AND AUTOLOGOUS STEM CELL TRANSPLANTATION FOLLOWED BY POLATUZUMAB VEDOTIN (PV) IMMNOCONJUGATE THERAPY IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA
|
Gardenswartz, A. |
|
|
121 |
S |
p. S24-S25 |
artikel |
105 |
SAFETY PROFILE OF RITUXIMAB IN INITIAL TREATMENT OF CHILDREN AND ADOLESCENTS WITH MATURE B-NHL
|
Finger, J. |
|
|
121 |
S |
p. S24 |
artikel |
106 |
SEARCHING FOR THE CAUSES OF ANAPLASTIC LARGE CELL LYMPHOMA
|
James, E. |
|
|
121 |
S |
p. S45 |
artikel |
107 |
SHEDDING LIGHT ON GREY ZONE LYMPHOMA
|
Mason, N. |
|
|
121 |
S |
p. S57 |
artikel |
108 |
SINGLE-CELL TRANSCRIPTOMIC ANALYSIS OF PEDIATRIC BURKITT LYMPHOMA REVEALS INTRA-TUMOR HETEROGENEITY
|
Corinaldesi, C. |
|
|
121 |
S |
p. S22-S23 |
artikel |
109 |
SOX11 AND EPSTEIN–BARR VIRUS MAY SUBSTITUTE EACH OTHER IN EARLY PATHOGENESIS OF BURKITT LYMPHOMA
|
Sureda-Gómez, M. |
|
|
121 |
S |
p. S44 |
artikel |
110 |
SUMMARY OF THE MID-TERM EFFICACY OF CHINA NET CHILDREN LYMPHOMA (CNCL)–MATURE B-CELL LYMPHOMA-2017 REGIMEN IN THE TREATMENT OF PEDIATRIC BURKITT’S LYMPHOMA
|
Meng, Z. |
|
|
121 |
S |
p. S20 |
artikel |
111 |
SURVIVAL OF PATIENTS WITH EXTRANODAL NK-CELL LYMPHOMA IN THE UNITED STATES
|
Xavier, A. |
|
|
121 |
S |
p. S7 |
artikel |
112 |
TARGETED THERAPY INCREASES PD-L1 PROTEIN EXPRESSION IN CELL LINES OF MEDIASTINAL LYMPHOMA
|
Hutchison, R. |
|
|
121 |
S |
p. S43-S44 |
artikel |
113 |
THE CHALLENGE OF PROSPECTIVE DISTINCTION BETWEEN NON-NEOPLASTIC VERUS NEOPLASTIC EBV-ASSOCIATED HLH
|
Gulati, N. |
|
|
121 |
S |
p. S6-S7 |
artikel |
114 |
THE MITOCHONDRIAL CHAPERONE TRAP1: A BRIDEGE BETWEEN METABOLIC REWIRING AND EPIGENETIC REMODELING IN DLBCL
|
Ferrone, L. |
|
|
121 |
S |
p. S45-S46 |
artikel |
115 |
THE PROFILING OF CIRCULATING TUMOR DNA IN PEDIATRIC MATURE B-CELL NON-HODGKIN LYMPHOMA (B-NHL): A MULTICENTER, PROSPECTIVE CLINICAL STUDY
|
Wang, J. |
|
|
121 |
S |
p. S30-S32 |
artikel |
116 |
THE PROGNOSTIC VALUE OF BULK DISEASE IN TREATMENT OUTCOMES OF PEDIATRIC HODGKIN LYMPHOMA TREATED ACCORDING TO EURONET PROTOCOL
|
Eldeen, N. Ezz |
|
|
121 |
S |
p. S60-S61 |
artikel |
117 |
Title Page
|
|
|
|
121 |
S |
p. i |
artikel |
118 |
TOXICITY OF TARGETED THERAPY WITH IMATINIB IN PATIENT WITH NIJMEGEN BREAKAGE SYNDROME AND T -LYMPHOBLASTIC LYMPHOMA/LEUKEMIA HARBORING ZBTB16-ABL1 FUSION
|
Krenova, Z. |
|
|
121 |
S |
p. S69-S70 |
artikel |
119 |
TP53 STATUS RISK STRATIFIES PATIENTS WITH CLINICALLY DEFINED HIGH-RISK DISEASE PAEDIATRIC B-CELL NON-HODGKIN LYMPHOMA
|
Newman, Alexander M. |
|
|
121 |
S |
p. S51-S52 |
artikel |
120 |
TRANSCRIPTION AND REPLICATION IMPAIRMENTS DRIVING MYC-INDUCED B AND T CELL LYMPHOBLASTIC LYMPHOMAS
|
Sinha, A. |
|
|
121 |
S |
p. S37 |
artikel |
121 |
TREATING LYMPHOMA IN THE PANDEMIC ERA: WHAT WE LEARNED FROM OUR EXPERIENCE AT FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI
|
Gattuso, G. |
|
|
121 |
S |
p. S55-S56 |
artikel |
122 |
UNUSUAL LYMPHOMA WITH CLINICAL AND PATHOLOGICAL FEATURES OF SUBCUTANEOUS PANNICULITIS-LIKE PERIPHERIAL T CELL LYMPHOMA (SPTCL) BUT WITH GAMMA/DELTA IMMUNOPHENOTYPE AND BIALLELIC HAVCR2 GERMLINE MUTATIONS
|
Molloy, F. |
|
|
121 |
S |
p. S53 |
artikel |
123 |
UPFRONT PEMBROLIZUMAB IN THERAPY OF NIJMEGEN BREAKAGE SY (NBS) PATIENT WITH HODGKIN LYMPHOMA DEMONSTRATED HIGH EFFICACY AND WAS WELL TOLERATED
|
Krenova, Z. |
|
|
121 |
S |
p. S59 |
artikel |
124 |
VARIANT ALK-FUSION POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA (ALCL): A POPULATION-BASED COHORT OF THE NHL-BFM STUDY GROUP
|
Damm-Welk, C. |
|
|
121 |
S |
p. S28 |
artikel |
125 |
VARYING OUTCOMES OF MATURE T AND NK LYMPHOMA IN PEDIATRIC AND ADOLESCENT/YOUNG ADULT PATIENTS: A SINGLE INSTITUTION EXPERIENCE
|
Lin, C. |
|
|
121 |
S |
p. S54 |
artikel |
126 |
WHOLE GENOME SEQUENCING REVEALS MOLECULAR HETEROGENEITY OF DIFFUSE B-CELL LYMPHOMAS IN CHILDREN WITH NIJMEGEN BREAKAGE SYNDROME
|
Pastorczak, A. |
|
|
121 |
S |
p. S50 |
artikel |